Intersect ENT Inc (XENT) CFO Sells $433,951.35 in Stock

Intersect ENT Inc (NASDAQ:XENT) CFO Jeryl L. Hilleman sold 12,835 shares of the stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $33.81, for a total transaction of $433,951.35. Following the completion of the transaction, the chief financial officer now owns 25,767 shares in the company, valued at $871,182.27. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Intersect ENT Inc (NASDAQ XENT) opened at $34.35 on Friday. The company has a market cap of $1,020.65, a price-to-earnings ratio of -54.52 and a beta of 0.67. Intersect ENT Inc has a 52-week low of $11.75 and a 52-week high of $35.34.

Intersect ENT (NASDAQ:XENT) last announced its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.05. The firm had revenue of $22.31 million for the quarter, compared to the consensus estimate of $21.53 million. Intersect ENT had a negative net margin of 19.81% and a negative return on equity of 15.96%. The company’s revenue was up 20.8% on a year-over-year basis. During the same period last year, the firm earned ($0.22) EPS. equities analysts forecast that Intersect ENT Inc will post -0.63 EPS for the current year.

Several research firms have weighed in on XENT. Guggenheim reiterated a “buy” rating and issued a $41.00 price target on shares of Intersect ENT in a research report on Friday, December 15th. Zacks Investment Research upgraded shares of Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a research report on Thursday, October 5th. BidaskClub upgraded shares of Intersect ENT from a “sell” rating to a “hold” rating in a research report on Saturday, December 30th. BTIG Research reiterated a “hold” rating on shares of Intersect ENT in a research report on Tuesday, November 7th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $36.00 price target on shares of Intersect ENT in a research report on Monday, December 11th. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $33.38.

Several hedge funds have recently made changes to their positions in the company. Simplex Trading LLC bought a new stake in shares of Intersect ENT during the 4th quarter valued at $242,000. GSA Capital Partners LLP bought a new stake in shares of Intersect ENT during the 3rd quarter valued at $926,000. Iguana Healthcare Management LLC raised its position in shares of Intersect ENT by 28.6% during the 3rd quarter. Iguana Healthcare Management LLC now owns 90,000 shares of the medical equipment provider’s stock valued at $2,804,000 after purchasing an additional 20,000 shares during the period. Neuberger Berman Group LLC raised its position in shares of Intersect ENT by 8.0% during the 3rd quarter. Neuberger Berman Group LLC now owns 802,521 shares of the medical equipment provider’s stock valued at $24,999,000 after purchasing an additional 59,620 shares during the period. Finally, California Public Employees Retirement System raised its position in shares of Intersect ENT by 134.8% during the 3rd quarter. California Public Employees Retirement System now owns 21,833 shares of the medical equipment provider’s stock valued at $680,000 after purchasing an additional 12,533 shares during the period. Hedge funds and other institutional investors own 86.31% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Intersect ENT Inc (XENT) CFO Sells $433,951.35 in Stock” was originally posted by Markets Daily and is the property of of Markets Daily. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.themarketsdaily.com/2018/01/14/intersect-ent-inc-xent-cfo-sells-433951-35-in-stock.html.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Insider Buying and Selling by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply